Share This Author
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study…
- B. Giantonio, P. Catalano, A. Benson
- Medicine, BiologyJournal of Clinical Oncology
- 20 April 2007
The addition of bevacizumab to oxaliplatin, fluorouracil, and leucovorin improves survival duration for patients with previously treated metastatic colorectal cancer.
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.
- L. Saltz, N. Meropol, P. Loehrer, M. Needle, J. Kopit, R. Mayer
- MedicineJournal of Clinical Oncology
- 1 April 2004
Cetuximab on this once-weekly schedule has modest activity and is well-tolerated as a single agent in patients with chemotherapy-refractory colorectal cancer whose tumors express the epidermal growth factor receptor.
Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.
- Steven J. Cohen, C. Punt, N. Meropol
- Medicine, BiologyJournal of Clinical Oncology
- 1 July 2008
The number of CTCs before and during treatment is an independent predictor of PFS and OS in patients with metastatic colorectal cancer and Baseline and follow-up CTC levels remained strong predictors of P FS and OS after adjustment for clinically significant factors.
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.
- F. Kabbinavar, H. Hurwitz, E. Bergsland
- Medicine, BiologyJournal of Clinical Oncology
- 2003
The encouraging results of this randomized trial support further study of bevacizumab 5 mg/kg plus chemotherapy as first-line therapy for metastatic colorectal cancer.
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.
- S. Khambata-Ford, C. Garrett, D. Mauro
- Biology, MedicineJournal of Clinical Oncology
- 1 May 2007
Gene expression profiles showed that patients with tumors that express high levels of the EGFR ligands epiregulin and amphireGulin and patients with wild-type K-ras are more likely to have disease control on cetuximab treatment.
Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.
- J. Spratlin, R. Cohen, S. Eckhardt
- Medicine, BiologyJournal of Clinical Oncology
- 10 February 2010
Objective antitumor activity and antiangiogenic effects were observed over a wide range of dose levels, suggesting that ramucirumab may have a favorable therapeutic index in treating malignancies amenable to VEGFR-2 inhibition.
American Society of Clinical Oncology guidance statement: the cost of cancer care.
- N. Meropol, D. Schrag, L. Schnipper
- Medicine, Political ScienceJournal of Clinical Oncology
- 10 August 2009
A clear understanding of the factors that drive these costs, as well as potential modifications to the current cancer care system, are required to ensure that all Americans have access to high-quality, cost-effective care.
American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options.
- L. Schnipper, N. Davidson, American Society of Clinical Oncology
- Medicine, Political ScienceJournal of Clinical Oncology
- 22 June 2015
The high costs associated with cancer care have created a difficult situation for patients and the oncologists who care for them and will require greater understanding of all the risks and benefits of various treatment options as well as the consequences of specific choices.
Delivering affordable cancer care in high-income countries.
- R. Sullivan, J. Peppercorn, M. Aapro
- Medicine, Political ScienceThe Lancet Oncology
- 1 September 2011
Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel.
- M. Rothenberg, N. Meropol, E. Poplin, E. Van Cutsem, S. Wadler
- MedicineJournal of Clinical Oncology
- 15 September 2001
Close clinical monitoring, early recognition of toxicities and toxicity syndromes, aggressive therapeutic intervention, and withholding therapy in the presence of unresolved drug-related toxicities is recommended for patients receiving IFL or other intensive chemotherapy regimens.
...
...